You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
9 November 2026 - Biopharmaceutical company Janux Therapeutics Inc (Nasdaq: JANX) on Monday reported positive initial Phase 1 results for JANX011 in healthy volunteers, supporting plans to advance the investigational therapy into clinical studies for...
9 November 2026 - Genome research company Illumina Inc (NASDAQ: ILMN) announced on Monday that it has expanded its molecular residual disease (MRD) research portfolio with an early access programme for a new ultrasensitive duplex sequencing workflow ...
9 November 2026 - French vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) on Monday announced positive results from two Phase 2 trials of S4V2, its tetravalent bioconjugate vaccine candidate targeting shigellosis.The studies demonstrated...
9 November 2026 - Diagnostic company Photocure ASA (OSE: PHO) confirmed on Monday that the anticipated Medicare coverage timeline for its AssureMDx bladder cancer test remains aligned with its original acquisition assumptions, following a newly publi...
9 November 2026 - Biotechnology company Halozyme Therapeutics Inc (Nasdaq:HALO) announced on Friday that Johnson & Johnson (NYSE:JNJ) was granted accelerated approval from the US Food and Drug Administration (FDA) for RYBREVANT FASPRO (amivantama...
9 November 2026 - Commercial-stage biopharmaceutical company Bio-Thera Solutions Ltd (SHA:688177) announced on Monday that China's National Medical Products Administration (NMPA) has approved its marketing authorisation for BAT2506, a golimumab ...
9 November 2026 - Clinical-stage biotechnology company GlycoNex Inc (TPEx:4168) announced on Sunday that a marketing authorisation application for SPD8, its denosumab biosimilar candidate co-developed with Mitsubishi Gas Chemical (MGC), has been subm...